David W. Salzman, Ph.D.
Affiliations: | Gatehouse Bio |
Area:
RNA, microRNA, molecular biology, genetics, radiation therapy, translational scienceGoogle:
"David Salzman"Mean distance: (not calculated yet)
Cross-listing: Chemistry Tree
Parents
Sign in to add mentor| Henry M. Furneaux | grad student | 2004-2009 | University of Connecticut Health Center |
| Frank J. Slack | post-doc | 2009-2014 | Yale (Chemistry Tree) |
| Joanne B. Weidhaas | post-doc | 2009-2014 | Yale School of Medicine |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jung SY, Malhotra P, Nguyen KC, et al. (2019) The KRAS-variant and its impact on normal breast epithelial cell biology. Cell Death and Differentiation |
| Weidhaas JB, Scheffler AW, Salzman D, et al. (2019) A germline microRNA-based biomarker signature of immune-associated toxicity to anti-PD1/PDL1 therapy. Journal of Clinical Oncology. 37: 96-96 |
| Weidhaas JB, Telesca D, Kalbasi A, et al. (2017) Germ-line biomarkers disrupting microRNA regulatory pathways to predict toxicity and response to anti-PD-1 and anti-PD-L1 therapies. Journal of Clinical Oncology. 35: 3040-3040 |
| Gautheret D, Taube JH, Mani SA, et al. (2016) Erratum: The Non-Coding RNA Journal Club: Highlights on Recent Papers-4. Non-Coding RNA 2016, 2, 9. Non-Coding Rna. 2 |
| Gautheret D, Taube JH, Mani SA, et al. (2016) The Non-Coding RNA Journal Club: Highlights on Recent Papers-4. Non-Coding Rna. 2 |
| Salzman DW, Nakamura K, Nallur S, et al. (2016) miR-34 activity is modulated through 5'-end phosphorylation in response to DNA damage. Nature Communications. 7: 10954 |
| McVeigh TP, Jung SY, Kerin MJ, et al. (2015) Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. Cell Cycle (Georgetown, Tex.). 14: 2091-9 |
| Weidhaas JB, McVeigh TP, Jung SY, et al. (2015) Estrogen withdrawal, breast cell transformation, and multiple breast cancer risk in women with the KRAS-variant. Journal of Clinical Oncology. 33: e12541-e12541 |
| Saridaki Z, Weidhaas JB, Lenz HJ, et al. (2014) A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4499-510 |
| Dorairaj JJ, Salzman DW, Wall D, et al. (2014) A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer. Bmc Cancer. 14: 421 |